Boston Family Office LLC Lowers Position in Pfizer Inc. (PFE)
Boston Family Office LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.5% during the second quarter, Holdings Channel reports. The institutional investor owned 147,562 shares of the biopharmaceutical company’s stock after selling 2,309 shares during the period. Boston Family Office LLC’s holdings in Pfizer were worth $5,196,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in the stock. Ronna Sue Cohen increased its position in Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 35 shares during the period. Forte Capital LLC ADV increased its position in Pfizer by 0.4% in the first quarter. Forte Capital LLC ADV now owns 8,589 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 36 shares during the period. Naples Global Advisors LLC increased its position in Pfizer by 0.4% in the second quarter. Naples Global Advisors LLC now owns 24,327 shares of the biopharmaceutical company’s stock valued at $857,000 after buying an additional 85 shares during the period. Lincoln Capital LLC increased its position in Pfizer by 1.1% in the second quarter. Lincoln Capital LLC now owns 8,443 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 94 shares during the period. Finally, Donald L. Hagan LLC increased its position in Pfizer by 0.9% in the second quarter. Donald L. Hagan LLC now owns 11,006 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 97 shares during the period. Hedge funds and other institutional investors own 69.65% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.53% on Friday, hitting $33.47. The stock had a trading volume of 8,413,108 shares. The stock has a 50 day moving average of $34.33 and a 200 day moving average of $34.17. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39. The firm has a market cap of $203.02 billion, a price-to-earnings ratio of 29.67 and a beta of 0.86.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business’s revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.56 earnings per share. Equities analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.57%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
Several research firms recently weighed in on PFE. Argus reaffirmed a “buy” rating and set a $39.00 price objective on shares of Pfizer in a research report on Sunday, August 28th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Jefferies Group reaffirmed a “buy” rating and set a $42.00 price objective (up previously from $41.00) on shares of Pfizer in a research report on Tuesday, June 14th. Vetr cut shares of Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price objective for the company. in a research report on Tuesday, June 28th. Finally, Citigroup Inc. reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Pfizer in a research report on Wednesday, August 3rd. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Pfizer currently has a consensus rating of “Buy” and a consensus price target of $38.78.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.